Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N5AS | ISIN: US59503A2042 | Ticker-Symbol: CY9D
Tradegate
20.12.24
08:50 Uhr
0,918 Euro
-0,010
-1,08 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MICROBOT MEDICAL INC Chart 1 Jahr
5-Tage-Chart
MICROBOT MEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,9500,99021.12.
0,8930,96220.12.

Aktuelle News zur MICROBOT MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoMicrobot Medical Inc. - 8-K, Current Report2
10.12.Microbot Medical Inc.: Microbot Medical CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access11
10.12.Microbot Medical submits Liberty surgical robot to FDA7
10.12.Microbot Medical Inc.: Microbot Medical Announces FDA Submission for the Commercialization of the LIBERTY Endovascular Robotic System62FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence Commercialization...
► Artikel lesen
10.12.Microbot Medical Inc. - 8-K, Current Report-
31.10.Microbot Medical Inc. - 8-K, Current Report14
MICROBOT MEDICAL Aktie jetzt für 0€ handeln
16.10.Microbot Medical Stock Rises After Completing ACCESS-PVI Trial13
15.10.Microbot Medical completes trial, set to submit surgical robot to FDA this year4
15.10.Microbot Medical completes human clinical trial in its ACCESS-PVI6
15.10.Microbot Medical completes key clinical trial, eyes FDA submission16
15.10.Microbot Medical Inc.: Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY during 2Q 2025109U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot...
► Artikel lesen
14.10.Microbot Medical droht Delisting von der Nasdaq aufgrund des Aktienkurses16
14.10.Microbot Medical faces Nasdaq delisting over share price5
11.10.Microbot Medical Inc. - 8-K, Current Report2
30.09.Microbot Medical nähert sich dem Ende der entscheidenden klinischen Studie22
30.09.Microbot Medical nears end of pivotal clinical trial1
30.09.Microbot Medical Inc.: Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up2
30.09.Microbot Medical Inc. - 8-K, Current Report4
17.09.Microbot Medical Inc.: Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System239BRAINTREE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully...
► Artikel lesen
11.09.Microbot Medical Inc. - 8-K, Current Report3
Seite:  Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1